Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire, in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You and must sign and date here.
Item VI. PREPARATION TIME
Examples of Item VI in a sentence
Failure to apply treatment properly will result in recall treatment as listen in Item VI above.
Transferring a pass to a third party — whether sold or given free of charge — is not permitted and represents a severe violation of the Conditions of Participation, in accordance with Item VI of the General Section of the Conditions of Participation.
Should you disagree with any amendments, please exercise your right to request that NCKU discontinue to collect, process or use your personal data according to Item VI of Article I.
Item VI The number of shares or total amount of the securities outstanding for each class of securities authorized.
Resolved, that the board approve Business Service & Finance Item VI.
More Definitions of Item VI
Item VI. This Item needs to be read by the investor and signed in acknowledgment.
Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You must sign and date here. If you prefer to send a wire transfer instead of a check, please mail or deliver your completed Investor Representation and Suitability Questionnaire to the address above and send the wire transfer using these instructions: Email: oxxxxxxxx@xxxxxxxx0000.xxx Phone: 900-000-0000 This Term Sheet Summary (the “Term Sheet”) summarizes the terms on which you and other qualified accredited investors (the “Investors”) are invited to make an investment (the “Investment”) in Shuttle Pharmaceuticals Holdings, Inc. a Delaware corporation. This Term Sheet is merely a summary of the terms and provisions of the Subscription Agreement (the “Subscription Agreement”), the form of which will be provided to you. Accordingly, this Term Sheet is qualified in its entirety by reference, and is subject in all instances, to the terms and provisions of the Subscription Agreement. You are advised to carefully review the terms and provisions of the Subscription Agreement, as well as the risk factors attached thereto, before making a decision concerning the Investment.
Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire, in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You and must sign and date here. Review and complete the Investor Representation & Suitability Questionnaire and deliver it to the email or address below along with payment for your investment. Email: xxxxxxxxx@xxxxxxxx0000.xxx Subject: Asset Entities Inc. – [Investor Name] Address: Boustead Securities, LLC 0 Xxxxxxx, Xxxxx 000 Xxxxxx, XX 00000 Bank Name: Banc of California Bank Address: 0 XxxXxxxxx Xxxxx Xxxxx Xxx, XX 00000 SWIFT Code: XXXXXX00 Routing #: 000000000 Account Name: Xxxxxx Securities Inc. Account #: 2030650369 REF / Notes: Asset Entities Inc. – [Investor Name] Email: xxxxxxxxx@xxxxxxxx0000.xxx Phone: (000) 000-0000 Please read all instructions of this Investor Representation and Suitability Questionnaire (this “Questionnaire”) carefully before filling out this Questionnaire. This is a legally binding document. If you need assistance, please call 000-000-0000 or by email at xxxxxxxxx@xxxxxxxx0000.xxx.
Item VI. Payment to the Assignor on Funding Date: Item VII: Percentage Assigned: ___% (Expressed as a percentage of the total aggregate Commitments of the Bank Group, carry out to 10 decimal places; upon effectiveness of the Assignment as provide in the Credit Agreement, this will constitute the Assignee’s “Pro Rata Share” Item VIII: Revised Percentage of the Assignor: ___% (carry out to 10 decimal places; upon effectiveness of the Assignment as provided in the Credit Agreement, this will constitute the Assignor’s “Pro Rata Share”) Bank: Initial Commitment: Percentage: U.S. Bank $ 35,000,000 23.333333333333 % JX Xxxxxx Cxxxx $ 22,500,000 15.000000000000 % Wxxxx Fargo $ 22,500,000 15.000000000000 % Hxxxxx Bank $ 15,000,000 10.000000000000 % Key Bank $ 15,000,000 10.000000000000 % Bank of America $ 10,000,000 6.666666666667 % Union Bank of California $ 15,000,000 10.000000000000 % Bank Hapoalim $ 7,500,000 5.000000000000 % Bank of the West $ 7,500,000 5.000000000000 % % Total: $ 150,000,000 100.000000000000 %
Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You must sign and date here. If you prefer to send a wire transfer instead of a check, please mail or deliver your completed Investor Representation and Suitability Questionnaire to the address above and send the wire transfer using these instructions: Email: oxxxxxxxx@xxxxxxxx0000.xxx Phone: 700-000-0000 Please read all instructions of this Investor Representation and Suitability Questionnaire (this “Questionnaire”) carefully before filling out this Questionnaire. This is a legally binding document. If you need assistance, please call 900-000-0000 or by email at bxxxxxx@xxxxxxxx0000.xxx.
Item VI. Payment to the Assignor on Funding Date: Item VII: Percentage Assigned: ___% (Expressed as a percentage of the total aggregate Commitments of the Bank Group, carry out to 10 decimal places; upon effectiveness of the Assignment as provide in the Credit Agreement, this will constitute the Assignee’s “Pro Rata Share” Item VIII: Revised Percentage of the Assignor: ___% (carry out to 10 decimal places; upon effectiveness of the Assignment as provided in the Credit Agreement, this will constitute the Assignor’s “Pro Rata Share”) Bank: Initial Commitment: Percentage: U.S. Bank $ 40,000,000 40.00000 % JX Xxxxxx Chase $ 25,000,000 25.00000 % Wxxxx Fargo $ 25,000,000 25.00000 % Bank Hapoalim $ 10,000,000 10.00000 % Total: $ 100,000,000 100.00000 %
Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You must sign and date here. If you prefer to send a wire transfer instead of a check, please mail or deliver your completed Investor Representation and Suitability Questionnaire to the address above and send the wire transfer using these instructions: FOR VALUE RECEIVED, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Shuttle Pharma” or the “Maker”), hereby promises to pay to the order of________________ (the “Subscriber”), or its registered assigns (together with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof).